Basel Medical Group Ltd
BMGL
$4.45
$0.040.91%
NASDAQ
| 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | ||
|---|---|---|---|---|---|
| Net Income | -37.40% | -37.07% | 125.71% | 127.49% | |
| Total Depreciation and Amortization | 10.56% | 11.07% | -15.19% | -14.52% | |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | |
| Total Other Non-Cash Items | -221.24% | -221.77% | 173.14% | 173.67% | |
| Change in Net Operating Assets | 1,804.87% | 1,816.57% | -536.37% | -539.90% | |
| Cash from Operations | 52.95% | 53.73% | -86.19% | -86.08% | |
| Capital Expenditure | 100.00% | 100.00% | -70.59% | -70.59% | |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | |
| Cash Acquisitions | -- | -- | -- | -- | |
| Divestitures | -- | -- | -- | -- | |
| Other Investing Activities | -- | -- | -- | -- | |
| Cash from Investing | 100.00% | 100.00% | -70.59% | -70.59% | |
| Total Debt Issued | 102.94% | 102.94% | -87.64% | -87.64% | |
| Total Debt Repaid | -118.03% | -118.03% | 85.16% | 85.16% | |
| Issuance of Common Stock | -- | -- | -- | -- | |
| Repurchase of Common Stock | -- | -- | -- | -- | |
| Issuance of Preferred Stock | -- | -- | -- | -- | |
| Repurchase of Preferred Stock | -- | -- | -- | -- | |
| Total Dividends Paid | -- | -- | -- | -- | |
| Other Financing Activities | -67,000.00% | -67,000.00% | -- | -- | |
| Cash from Financing | 22.45% | 22.05% | 65.12% | 64.85% | |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | |
| Net Change in Cash | 588.45% | 591.24% | -97.86% | -99.41% | |